布鲁顿酪氨酸激酶抑制剂治疗原发中枢神经系统淋巴瘤的研究进展OA
Research progress of Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma
原发中枢神经系统淋巴瘤(PCNSL)是一种高度侵袭性结外弥漫大B细胞淋巴瘤.尽管其对放化疗敏感,但基于大剂量甲氨蝶呤的传统标准治疗方案仍面临药物毒性大、复发率高及老年患者耐受性差等挑战.鉴于PCNSL高频伴发MYD88与CD79B突变,具有优异血脑屏障穿透能力的布鲁顿酪氨酸激酶抑制剂(BTKi)有望成为改善其预后的重要精准治疗策略.本文综述了BTKi在PCNSL治疗中的最新临床进展.
Primary central nervous system lymphoma(PCNSL)is a highly aggressive extranodal diffuse large B-cell lymphoma.Although sensitive to chemoradiotherapy,traditional standard treatment regimens based on high-dose methotrexate still face challenges,such as high toxicity,high recurrence rate,and poor tolerance in older patients.Given the high frequency of MYD88 and CD79B mutations in PCNSL,Bruton's tyrosine kinase inhibitors(BTKi),with their excellent blood-brain-barrier penetration capabilities,are expected to become an important precision treatment strategy for improving prognosis.In this article,the latest clinical progress of BTKi in the treatment of PCNSL is reviewed.
卞仁杰;孙鹏;王军;颜晓菁
中国医科大学附属第一医院 血液内科,沈阳 110001中国医科大学附属第一医院 眼科,沈阳 110001中国医科大学附属第一医院 神经外科,沈阳 110001中国医科大学附属第一医院 血液内科,沈阳 110001
医药卫生
布鲁顿酪氨酸激酶抑制剂原发性中枢神经系统淋巴瘤治疗进展
Bruton's tyrosine kinase inhibitorsprimary central nervous system lymphomatreatment progress
《中国医科大学学报》 2026 (5)
385-388,395,5
国家血液系统疾病临床医学研究中心转化研究开放课题面上项目(2020ZKMB06)辽宁省科技计划联合计划(2023JH2/101700092)
评论